Cerus (CERS) Reports In-Line Q4 EPS

Cerus (NASDAQ: CERS) reported Q4 EPS of ($0.09), in-line with the analyst estimate of ($0.09). Revenue for the quarter came in at $33.6 million versus the consensus estimate of $32.42 million.

“The COVID-19 pandemic has fundamentally altered the way the world thinks about pandemic preparedness. As we recognize a record quarter and year for our business, there remains much work to do with blood centers and hospitals around the world to ensure the safety and availability of the blood supply and protect patients from infectious viral diseases and bacterial contaminants. During a year unlike any other, I am proud of the significant commercial momentum we generated in 2020 to help advance pathogen reduced blood products towards the standard of care in transfusion medicine,” said William ‘Obi’ Greenman, Cerus’ president and chief executive officer. “With customers continuing to increase production of INTERCEPT platelets, we are poised for another year of solid top-line growth in 2021. Additionally, our team is working to launch our recently FDA approved Pathogen Reduced Cryoprecipitated Fibrinogen Complex product and to advance our pipeline programs. While we have made tremendous progress, we still have much work to do to realize our mission to safeguard the global blood supply. We look forward to updating our stakeholders as we make progress towards our key milestones over the course of the year.”

GUIDANCE:

Cerus sees FY2021 revenue of $106-110 million, versus the consensus of $113.07 million.

For earnings history and earnings-related data on Cerus (CERS) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• SPS Commerce (SPSC) Tops Q1 EPS by 12c
• Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c